# Gemmus Pharma

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gemmus-pharma

- Industry: Pharmaceuticals
- Headquarters: San Francisco, US
- Website: www.gemmuspharma.com
- Total disclosed funding: $5.1M
- Latest round: Series B (May 13, 2014)
- Investors on record: 5

## About

Gemmus Pharma Inc. is a biopharmaceutical company focused on developing innovative treatments that advance healthcare solutions and improve patient outcomes through advanced drug delivery systems.Gemmus Pharma Inc. specializes in biopharmaceuticals aimed at enhancing drug delivery for various therapeutic areas. Founded in 2007 in San Francisco, US, the company has pivoted its focus to integrate advanced technologies into its product offerings. The firm is led by CEO Daryl Faulds, with founder William Guilford bringing extensive experience from previously founded ventures. In its latest funding round in May 2014, Gemmus raised USD 3.3 mn in Series B financing from various investors, bringing its total amount raised to USD 3.3 mn. The company has been involved in 2 deals to date.Gemmus Pharma Inc. offers a diverse range of biopharmaceutical products designed to meet the needs of its clients across the healthcare sector. Their innovative solutions enhance drug delivery efficiency, improve patient compliance, and drive better health outcomes. The company focuses on delivering technology-driven solutions that cater to healthcare providers, with specific emphasis on usability and integration. Gemmus Pharma's products are utilized across North America, Europe, and parts of Asia, establishing a robust presence in both established and emerging markets.The company generates revenue through multiple transaction models tailored to its clientele's needs. Gemmus engages in direct-to-consumer sales and B2B partnerships, employing a subscription-based pricing model for its flagship products. This model ensures a steady income stream while providing value to customers, allowing consistent access to essential tools and updates. A typical transaction scenario involves healthcare providers subscribing to a suite of integrated services that enhance drug delivery and patient management strategies, thus contributing to the company's overall financial stability.Gemmus Pharma Inc. plans to leverage its recent USD 3.3 mn Series B funding to further develop its biopharmaceutical products, with a focus on enhancing drug delivery systems. The company aims to launch new innovative treatments by mid-2025, targeting expansion into emerging markets in Asia and Latin America. The funds raised will support the development of these new products and the establishment of partnerships in these regions, allowing Gemmus to broaden its market presence significantly.

## Funding rounds

- Series B, May 13, 2014, $3.3M — The Angels' Forum, Tech Coast Angels, Life Science Angels, Inc., Wilmington Investor Network, BlueTree Allied Angels
- Series A, Jun 28, 2012, $1.8M — The Angels' Forum, Tech Coast Angels, Life Science Angels, Inc., Wilmington Investor Network, BlueTree Allied Angels

## Investors

- The Angels' Forum (https://capitalatlas.ai/funds/the-angels-forum) — Series A, Series B
- Tech Coast Angels — Series A, Series B
- Life Science Angels, Inc. — Series A, Series B
- Wilmington Investor Network — Series A, Series B
- BlueTree Allied Angels — Series A, Series B